Ghana begins clinical trial of Oxford’s CEPI-backed Lassa shot
Ghana has initiated clinical trials for the ChAdOx1 LassaJ vaccine, developed by the University of Oxford and supported by CEPI. The study aims to assess the safety and immune response of the vaccine in healthy adults to combat the threat of Lassa fever.
Why it matters
Developing a vaccine for Lassa fever is a significant public health priority for West Africa, where the disease causes severe illness and mortality.
Ghana has begun testing an experimental Lassa fever vaccine, with the first participants receiving their doses at the Kintampo Health Research Centre in the Bono East Region.
The study is aimed at gathering more information about the safety of the vaccine, known as ChAdOx1 LassaJ, and how the human body responds to it.
The trial, which began on October 14, will involve up to 51 healthy adults aged between 18 and 55. It is part of research being conducted by the University of Oxford, with a similar trial taking place in the United Kingdom.
The research is supported by the Coalition for Epidemic Preparedness Innovations (CEPI), which is working to speed up the development of a safe and effective vaccine against Lassa fever.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in